eprintid: 17868 rev_number: 6 eprint_status: archive userid: 2 dir: disk0/00/01/78/68 datestamp: 2025-11-06 23:30:11 lastmod: 2025-11-06 23:30:11 status_changed: 2025-11-06 23:30:11 type: article metadata_visibility: show creators_name: Cavalcante, Deivyd Vieira Silva creators_name: de Oliveira, Lilia Maria Lima creators_name: Husain, Noor creators_name: Mendes, Beatriz Ximenes creators_name: Santos, Ana Clara Felix de Farias creators_name: Borrigueiro, Luciana creators_name: Rosa, Lyria de Oliveira creators_name: Ndikuryayo, Christian creators_name: Amorim, Sarah Soares creators_name: Mohan, Lalit creators_name: Lopes, Fabiana Castro Porto Silva title: Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis ispublished: pub subjects: uneat_bm divisions: uneatlantico_produccion_cientifica full_text_status: none abstract: Background Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 % of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition. Methods PubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 % confidence intervals were performed for outcomes. Results Nine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 % (95 % CI: 76.60-97.15). However, a relapse was observed in 11.42 % (95 % CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 %; 95 % CI: 21.81–90.33), followed by fever in 29.93 % of cases (95 % CI: 5.09–77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 % (95 % CI: 3.84–58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 % (95 % CI: 3.97–43.27). Nausea or vomiting, although less severe, affected 12.36 % of patients (95 % CI: 4.81–28.25). Conclusions These findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks. date: 2026-02 publication: Diagnostic Microbiology and Infectious Disease volume: 114 number: 2 pagerange: 117160 id_number: doi:10.1016/j.diagmicrobio.2025.117160 refereed: TRUE issn: 07328893 official_url: http://doi.org/10.1016/j.diagmicrobio.2025.117160 access: close language: en citation: Artículo Materias > Biomedicina Universidad Europea del Atlántico > Investigación > Artículos y libros Cerrado Inglés Background Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 % of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition. Methods PubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 % confidence intervals were performed for outcomes. Results Nine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 % (95 % CI: 76.60-97.15). However, a relapse was observed in 11.42 % (95 % CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 %; 95 % CI: 21.81–90.33), followed by fever in 29.93 % of cases (95 % CI: 5.09–77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 % (95 % CI: 3.84–58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 % (95 % CI: 3.97–43.27). Nausea or vomiting, although less severe, affected 12.36 % of patients (95 % CI: 4.81–28.25). Conclusions These findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks. metadata Cavalcante, Deivyd Vieira Silva; de Oliveira, Lilia Maria Lima; Husain, Noor; Mendes, Beatriz Ximenes; Santos, Ana Clara Felix de Farias; Borrigueiro, Luciana; Rosa, Lyria de Oliveira; Ndikuryayo, Christian; Amorim, Sarah Soares; Mohan, Lalit y Lopes, Fabiana Castro Porto Silva mail SIN ESPECIFICAR (2026) Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis. Diagnostic Microbiology and Infectious Disease, 114 (2). p. 117160. ISSN 07328893